BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37953066)

  • 1. Quantification of diffuse parenchymal lung disease in non-small cell lung cancer patients with definitive concurrent chemoradiation therapy for predicting radiation pneumonitis.
    An YC; Kim JH; Noh JM; Yang KM; Oh YJ; Park SG; Pyo HR; Lee HY
    Thorac Cancer; 2023 Dec; 14(36):3530-3539. PubMed ID: 37953066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
    Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
    Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptomatic Radiation Pneumonitis in NSCLC Patients Receiving EGFR-TKIs and Concurrent Once-daily Thoracic Radiotherapy: Predicting the Value of Clinical and Dose-volume Histogram Parameters.
    Yang X; Mei T; Yu M; Gong Y
    Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):409-419. PubMed ID: 35747920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel model integrating computed tomography-based image markers with genetic markers for discriminating radiation pneumonitis in patients with unresectable stage III non-small cell lung cancer receiving radiotherapy: a retrospective multi-center radiogenomics study.
    Li J; Li L; Tang S; Yu Q; Liu W; Liu N; Yang F; Zhang D; Yuan S
    BMC Cancer; 2024 Jan; 24(1):78. PubMed ID: 38225543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer.
    Robnett TJ; Machtay M; Vines EF; McKenna MG; Algazy KM; McKenna WG
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):89-94. PubMed ID: 10924976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease.
    Okumura M; Hojo H; Nakamura M; Hiyama T; Nakamura N; Zenda S; Motegi A; Hirano Y; Kageyama SI; Parshuram RV; Fujisawa T; Kuno H; Akimoto T
    Radiother Oncol; 2021 Aug; 161():47-54. PubMed ID: 34089755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer.
    Tsujino K; Hashimoto T; Shimada T; Yoden E; Fujii O; Ota Y; Satouchi M; Negoro S; Adachi S; Soejima T
    J Thorac Oncol; 2014 Jul; 9(7):983-990. PubMed ID: 24922010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).
    Glick D; Lyen S; Kandel S; Shapera S; Le LW; Lindsay P; Wong O; Bezjak A; Brade A; Cho BCJ; Hope A; Sun A; Giuliani M
    Clin Lung Cancer; 2018 Mar; 19(2):e219-e226. PubMed ID: 29066051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
    Ueki N; Matsuo Y; Togashi Y; Kubo T; Shibuya K; Iizuka Y; Mizowaki T; Togashi K; Mishima M; Hiraoka M
    J Thorac Oncol; 2015 Jan; 10(1):116-25. PubMed ID: 25376512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Interstitial Lung Abnormality on Concurrent Chemoradiotherapy-treated Stage III Non-small Cell Lung Cancer Patients.
    Jeong WG; Kim YH; Ahn SJ; Jeong JU; Lee BC; Cho IJ; Kim YH
    Anticancer Res; 2023 Apr; 43(4):1797-1807. PubMed ID: 36974810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exclusion of emphysematous lung from dose-volume estimates of risk improves prediction of radiation pneumonitis.
    Uchida Y; Tsugawa T; Tanaka-Mizuno S; Noma K; Aoki K; Shigemori W; Nakagawa H; Kinose D; Yamaguchi M; Osawa M; Ogawa E; Nakano Y
    Radiat Oncol; 2017 Oct; 12(1):160. PubMed ID: 28969651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Ventilation and Perfusion Imaging Correlates With the Dosimetric Parameters of Radiation Pneumonitis in Radiation Therapy Planning for Lung Cancer.
    Kimura T; Doi Y; Nakashima T; Imano N; Kawabata H; Nishibuchi I; Okabe T; Kenjo M; Ozawa S; Murakami Y; Nagata Y
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):778-87. PubMed ID: 26530746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease.
    Bahig H; Filion E; Vu T; Chalaoui J; Lambert L; Roberge D; Gagnon M; Fortin B; Béliveau-Nadeau D; Mathieu D; Campeau MP
    Pract Radiat Oncol; 2016; 6(5):367-374. PubMed ID: 27068780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer.
    Torre-Bouscoulet L; Muñoz-Montaño WR; Martínez-Briseño D; Lozano-Ruiz FJ; Fernández-Plata R; Beck-Magaña JA; García-Sancho C; Guzmán-Barragán A; Vergara E; Blake-Cerda M; Gochicoa-Rangel L; Maldonado F; Arroyo-Hernández M; Arrieta O
    Respir Res; 2018 Apr; 19(1):72. PubMed ID: 29690880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy.
    Zhou Z; Song X; Wu A; Liu H; Wu H; Wu Q; Liu Y; Li Y; Cai Y; Liang S
    Sci Rep; 2017 Jun; 7(1):2748. PubMed ID: 28584268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factor analysis of the development of severe radiation pneumonitis in patients with non-small cell lung cancer treated with curative radiotherapy, with focus on underlying pulmonary disease.
    Kim H; Hwang J; Kim SM; Choi J; Yang DS
    BMC Cancer; 2023 Oct; 23(1):992. PubMed ID: 37848850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer.
    Moreno M; Aristu J; Ramos LI; Arbea L; López-Picazo JM; Cambeiro M; Martínez-Monge R
    Clin Transl Oncol; 2007 Sep; 9(9):596-602. PubMed ID: 17921108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting radiation pneumonitis in locally advanced stage II-III non-small cell lung cancer using machine learning.
    Luna JM; Chao HH; Diffenderfer ES; Valdes G; Chinniah C; Ma G; Cengel KA; Solberg TD; Berman AT; Simone CB
    Radiother Oncol; 2019 Apr; 133():106-112. PubMed ID: 30935565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Chen K; Li S; Chen M; Jin Z; Sun X; Zhou S; Yang H
    BMC Cancer; 2024 Feb; 24(1):257. PubMed ID: 38395838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.
    Boonyawan K; Gomez DR; Komaki R; Xu Y; Nantavithya C; Allen PK; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):919-926. PubMed ID: 29976504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.